Inductive Bio
AI‑powered virtual lab that predicts ADMET at scale to accelerate small‑molecule drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
AI‑powered virtual lab that predicts ADMET at scale to accelerate small‑molecule drug discovery.
OncologyImmunologyCardiovascularNeurology
Technology Platform
Proprietary AI models (Beacon‑1) trained on a pre‑competitive ADMET data consortium, delivered through the Compass virtual lab and the Indy AI chemistry assistant.
Opportunities
Expansion of the AI ADMET platform to larger pharma customers, deeper integration with ARPA‑H safety initiatives, and scaling of virtual‑lab services across additional therapeutic areas.
Risk Factors
Dependence on high‑quality consortium data, adoption barriers in traditional discovery teams, and intense competition from other AI drug‑discovery platforms.
Competitive Landscape
Competes with AI‑driven discovery firms such as Insilico Medicine, Exscientia, and Atomwise; differentiates through its award‑winning Beacon‑1 models, pre‑competitive data consortium, and end‑to‑end virtual lab workflow.